Healthcare innovation is rapidly advancing, from new care delivery models to technologies reshaping how patients access treatment and support. Transforming those breakthroughs into scalable companies, however, requires more than promising ideas. It requires the right combination of clinical expertise, operational structure, and strategic capital.
At Boomerang Ventures, that transition is intentionally designed. Through its venture studio model, Boomerang works alongside founders to build healthcare companies with clinical insight, operational infrastructure, and early validation from day one.
The Boomerang team recently welcomed Arden Sorge, Investor Relations Manager, who plays a key role in that process. She works closely with Studio CEOs to refine fundraising strategies, prepare for investor diligence, and build relationships across venture firms, angels, family offices, and healthcare investors.
Her work sits at the intersection of capital, storytelling, and ecosystem building—helping early-stage healthcare companies gain the momentum they need to scale.
We recently sat down with Arden to discuss her career path, Boomerang’s venture studio model, and how thoughtful investor relationships can accelerate healthcare innovation.
The Journey: How Arden Got Here
Q: You’ve described your “sweet spot” as the intersection of venture capital, community building, and strategic storytelling. What does that intersection look like in practice?
Arden:
In practice, it means helping founders translate innovation into a narrative that resonates with the right investors—and then activating the relationships that move those conversations forward.
Early-stage companies often have strong technology or clinical insight but may still be shaping how they communicate their vision, market opportunity, and path to scale. My role is helping founders align those elements into a clear investment story while building the investor relationships that allow that story to gain traction.
When strategy, narrative, and the right network come together, momentum starts to compound.
Why Boomerang + Why the Studio Model
Q: From your perspective, what makes Boomerang’s Studio approach especially powerful for founders preparing to raise capital?
Arden:
One of the biggest challenges in early-stage healthcare is that the path from concept to investable company can be long and complex. Boomerang’s Studio model is designed to shorten that path.
Before companies ever enter the fundraising market, they are already building alongside clinical leaders, operators, and healthcare experts who help validate the technology, refine the business model, and establish early operational infrastructure.
That preparation changes the dynamic of fundraising. Investors are not evaluating a raw concept; they’re seeing a company that has been shaped within a repeatable platform designed to reduce early formation risk and accelerate early milestones.
Investor Relations as a Strategic Growth Function
Q: How do you balance storytelling and data when helping founders present their companies to investors?
Arden:
At the earliest stages, investors are ultimately betting on the founder. That makes building a narrative that is both ambitious and credible incredibly important.
Storytelling provides the context—why the problem matters, why the timing is right, and why the founder is uniquely positioned to solve it. That’s what allows investors to understand both the vision and the opportunity.
The most compelling companies anchor that story in evidence—clinical validation, early traction, market insight, early signals of customer adoption, and thoughtful strategies around business model design and scalable growth.
Our goal is to ensure the narrative and data are structured and aligned. When founders clearly communicate the vision and the proof points behind it, the conversation shifts from “Is this interesting?” to “How large could this opportunity become?”
Building the Right Capital Relationships
Q: Your focus includes cultivating relationships with venture firms, angels, family offices, and healthcare investors. How do you approach building trust with capital partners?
Arden:
Trust really comes from consistency, transparency, and thoughtful alignment.
Every investor has a different thesis, stage focus, and perspective on risk. My approach is to take the time to understand those priorities so that when we share opportunities, they are genuinely relevant.
Over time, that authenticity and intentional engagement – sharing progress, challenges, and insights turn introductions into long-term partnerships. People sometimes forget that venture is deeply human. It’s as much an art as a science, and relationships are the backbone of almost every investment that happens.
Community Building & Momentum
Q: Community building has been a consistent theme in your career. Why is community essential—not just for founders—but for capital formation in healthcare innovation?
Arden:
Healthcare innovation rarely succeeds in isolation. Founders need input from clinicians, operators, health systems, regulators, and investors to truly understand how a product will function in the real world.
Strong ecosystems create the connective tissue between those stakeholders. They allow founders to validate ideas faster, investors to evaluate opportunities with greater confidence, and companies to move through the healthcare system more effectively. When founders are connected to the right ecosystem, fundraising stops being transactional and becomes collaborative.
Coming from a generalist background, I’ve found healthcare is one of the few industries where nearly every stakeholder in the care continuum can influence how a company learns, validates, and grows. That makes community engagement incredibly valuable, and in many ways, capital follows community.
Unique Value & Forward Vision
Q: What do you believe you uniquely bring to the Studio side of Boomerang?
Arden:
Many members of the Boomerang team come from clinical and healthcare operating backgrounds, which is incredibly valuable when building companies in this sector. My role complements that expertise by focusing on how those innovations are translated to the broader capital ecosystem.
I bring a programmatic, network-driven lens to investor relationships—helping ensure that every conversation founders have today helps open doors for the next milestone, partnership, or funding round.
The goal isn’t simply helping companies raise capital in the moment. It’s helping them build long-term investor relationships that support sustained growth.
Lightning Round
Q: If you could give founders one piece of advice before they enter fundraising mode, what would it be?
Arden:
Clarity is everything. You never know what doors might open from even the simplest conversation, especially when your narrative is clear and concise.
Investors respond to conviction and clarity, so founders and CEOs need to clearly articulate the problem they are solving, why the market timing is right, and why they are uniquely positioned to build the solution. When that clarity is present, every investor conversation becomes more meaningful and often leads to better feedback, introductions, and long-term relationships.
Remember, the worst answer you’ll get is “no”—and hearing “no” is part of the process. Feedback helps refine your approach and leads you to the right “yes.”
Q: What’s a quote, mindset, or principle you try to live by, especially when the work gets challenging?
Arden:
“You can lead a horse to water, but you can’t make it drink.”
You should never have to convince someone endlessly to believe in what you’re building. If an investor isn’t the right fit, that’s okay because it creates space for the ones who are.
The right collaborators—investors, advisors, and partners—see the value from the beginning and align with the mission. Those are the people who will ultimately help take you to the finish line.
Q: What’s a book, podcast, or newsletter you’ve been into lately that’s shaping how you think about venture or healthcare innovation?
Arden:
There’s no shortage of great resources. For listening, I tune into The Heart of Healthcare or Diary of a CEO. For quick insights, I read newsletters like Out of Pocket by Nikhil Krishnan or Second Opinion by Christina Farr.
I also find myself on Slack communities like HealthTech Nerds and VC Platform to catch up on industry buzz.
Looking Ahead
Q: For investors reading this, why should they lean into a relationship with Boomerang’s Studio companies?
Arden:
Boomerang’s Studio companies are built with intention from the very beginning.
They combine clinical insight, structured company formation, and early validation before they ever enter the market. That approach allows investors to evaluate opportunities that have already been shaped by experienced healthcare operators and validated within a repeatable platform.
For investors interested in early-stage healthcare innovation, it offers access to companies that are both ambitious and thoughtfully developed—along with the opportunity to build long-term relationships with the platform behind them.
Final Thoughts
As Boomerang continues expanding its venture studio portfolio, Arden works to ensure that founders and investors connect in ways that build lasting value. Through thoughtful storytelling, disciplined preparation, and strong capital networks, she helps early-stage healthcare companies move from promising innovation to scalable businesses.
About Arden Sorge
Arden Sorge serves as Investor Relations Manager at Boomerang Ventures, supporting the firm’s venture studio portfolio. She works closely with founders to refine fundraising strategy, prepare for investor diligence, and cultivate relationships with venture firms, angels, family offices, and healthcare investors.
Her work focuses on translating early-stage healthcare innovation into compelling investment opportunities while strengthening the capital networks that help companies scale.
Connect with Arden on LinkedIn or via email at [email protected].
